These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15737694)

  • 1. Chibby, a novel antagonist of the Wnt pathway, is not involved in Wilms tumor development.
    Zirn B; Wittmann S; Graf N; Gessler M
    Cancer Lett; 2005 Mar; 220(1):115-20. PubMed ID: 15737694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the gene encoding Chibby implicated as a tumour suppressor in colorectal cancer ?
    Gad S; Teboul D; Lièvre A; Goasguen N; Berger A; Beaune P; Laurent-Puig P
    BMC Cancer; 2004 Jul; 4():31. PubMed ID: 15245581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
    Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
    Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear accumulation of beta-catenin protein in Wilms' tumours.
    Koesters R; Niggli F; von Knebel Doeberitz M; Stallmach T
    J Pathol; 2003 Jan; 199(1):68-76. PubMed ID: 12474228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Target genes of the WNT/beta-catenin pathway in Wilms tumors.
    Zirn B; Samans B; Wittmann S; Pietsch T; Leuschner I; Graf N; Gessler M
    Genes Chromosomes Cancer; 2006 Jun; 45(6):565-74. PubMed ID: 16575872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors.
    Koesters R; Ridder R; Kopp-Schneider A; Betts D; Adams V; Niggli F; Briner J; von Knebel Doeberitz M
    Cancer Res; 1999 Aug; 59(16):3880-2. PubMed ID: 10463574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axin, the main component of the Wnt signaling pathway, is not mutated in kidney tumors in children.
    Miao J; Kusafuka T; Udatsu Y; Okada A
    Int J Mol Med; 2002 Apr; 9(4):377-9. PubMed ID: 11891531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors.
    Tissier F; Cavard C; Groussin L; Perlemoine K; Fumey G; Hagneré AM; René-Corail F; Jullian E; Gicquel C; Bertagna X; Vacher-Lavenu MC; Perret C; Bertherat J
    Cancer Res; 2005 Sep; 65(17):7622-7. PubMed ID: 16140927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canonical WNT signalling determines lineage specificity in Wilms tumour.
    Fukuzawa R; Anaka MR; Weeks RJ; Morison IM; Reeve AE
    Oncogene; 2009 Feb; 28(8):1063-75. PubMed ID: 19137020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTNNB1 (beta-catenin) mutation is rare in brain tumours but involved as a sporadic event in a brain metastasis.
    Lee CI; Hsu MY; Chou CH; Wang C; Lo YS; Loh JK; Howng SL; Hong YR
    Acta Neurochir (Wien); 2009 Sep; 151(9):1107-11. PubMed ID: 19582367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Wnt-signaling pathway is not implicated in tumorigenesis of Merkel cell carcinoma.
    Liu S; Daa T; Kashima K; Kondoh Y; Yokoyama S
    J Cutan Pathol; 2007 Jan; 34(1):22-6. PubMed ID: 17214850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies.
    Groen RW; Oud ME; Schilder-Tol EJ; Overdijk MB; ten Berge D; Nusse R; Spaargaren M; Pals ST
    Cancer Res; 2008 Sep; 68(17):6969-77. PubMed ID: 18757411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational analysis of Wnt signaling molecules in ameloblastoma with aberrant nuclear expression of beta-catenin.
    Tanahashi J; Daa T; Yada N; Kashima K; Kondoh Y; Yokoyama S
    J Oral Pathol Med; 2008 Oct; 37(9):565-70. PubMed ID: 18284543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dominant-stable beta-catenin expression causes cell fate alterations and Wnt signaling antagonist expression in a murine granulosa cell tumor model.
    Boerboom D; White LD; Dalle S; Courty J; Richards JS
    Cancer Res; 2006 Feb; 66(4):1964-73. PubMed ID: 16488995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of APC/beta-catenin genes mutations and Wnt signalling pathway in desmoid-type fibromatosis.
    Jilong Y; Jian W; Xiaoyan Z; Xiaoqiu L; Xiongzeng Z
    Pathology; 2007 Jun; 39(3):319-25. PubMed ID: 17558858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
    Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
    J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Codon 45 of the beta-catenin gene, a specific mutational target site of Wilms' tumor.
    Kusafuka T; Miao J; Kuroda S; Udatsu Y; Yoneda A
    Int J Mol Med; 2002 Oct; 10(4):395-9. PubMed ID: 12239584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced expression of beta-catenin inhibitor Chibby in colon carcinoma cell lines.
    Schuierer MM; Graf E; Takemaru K; Dietmaier W; Bosserhoff AK
    World J Gastroenterol; 2006 Mar; 12(10):1529-35. PubMed ID: 16570344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. beta-Catenin mutation and its nuclear localization are confirmed to be frequent causes of Wnt signaling pathway activation in pilomatricomas.
    Xia J; Urabe K; Moroi Y; Koga T; Duan H; Li Y; Furue M
    J Dermatol Sci; 2006 Jan; 41(1):67-75. PubMed ID: 16378715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
    Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M
    Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.